Abiopharma

🔍 Kwong Connie H. (Executive)

Company: MAXLINEAR, INC (MXL)

Report Date: 2026-08-31

Detailed Transactions and Holdings:

• Acquired 1,110 shares of Common Stock (Direct)
  Date: 2026-08-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 20,482.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,110 shares of Common Stock at $59.91 per share (Direct)
  Date: 2026-08-31 | Code: F | equity_swap_involved: 0 | shares_owned_after: 19,372.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 1,110 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-31 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F3, F3

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock.
• F2: The Reporting Person deferred delivery of shares of Common Stock issuable upon the vesting of RSUs on August 20, 2026. On August 31, 2026, the deferred shares of Common Stock were delivered to the Reporting Person. The closing price of the Issuer's Common Stock on August 31, 2026 was the settlement price used to calculate the shares withheld.
• F3: Subject to the Reporting Person's continuing to be a Service Provider (as defined in the 2010 Equity Incentive Plan) through each applicable vesting date, twenty five percent (25%) of the 8,506 RSUs subject to the award vested on August 20, 2023, and twenty five percent (25%) of the RSUs subject to the award vests annually on each August 20 thereafter, such that the award will be fully vested on August 20, 2026.